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Introduction
First described by Gavini et al. in 1979, Serratia fonticola is a
member of the Enterobacteriaceae family found in a wide array of
environments, including drinking water, soil and sewage [1,2]. In
1985, Farmer et al. detailed biochemical identiﬁcation of several
Enterobacteriaceae organisms found among human specimens sent
to the Centers for Disease Control and Prevention [3]. Speciﬁcally,
they detected S. fonticola isolates among clinical samples obtained
from wounds and respiratory tracts, but not urine, distinguishing
them from other Serratia spp. based in part on the lack of
extracellular DNase, gelatinase and lipase.
Only 5 case reports describe human S. fonticola infections. The
ﬁrst was a 73-year-old womanwith a thigh abscess and bacteremia
secondary to infected hardware placed following a car accident
5months previously [4]. A second casewas a 15-year-oldmalewith
delayed septic arthritis of his knee due to a retained foreign body
following a bike accident [5]. Two more cases involved poly-
microbial skin and soft tissue infections following trauma,while the
ﬁfth case was an immunocompromised male with diarrhea
attributed to S. fonticola [6–8].
Here we present a case report of a patient who developed
urosepsis due to S. fonticola. We conducted a retrospective review
of clinical cultures that grew S. fonticola and reviewed prior
literature, using the term ‘‘Serratia fonticola’’ to query PubMed. To
the best of our knowledge, this is the ﬁrst description of S. fonticola
as a pathogen associated with the urinary tract.
Case report
A 67-year-old male sustained a combat injury in Vietnam
resulting in T12 paraplegia. He relied upon assisted bowel care and
a chronic indwelling urethral catheter to address his neurogenic
bowel and bladder, respectively. Additional comorbidities includ-
ed hypertension, sleep apnea, and syndrome of inappropriate
antidiuretic hormone secretion (SIADH). Due to the deteriorating
health of his primary caregiver, the patient agreed to placement in
a Veterans Affairs long-term care ward specializing in residents
with spinal cord injury. During his 4th month in the long-term
ward, he reported anxiety, malaise and nausea with an episode of
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A B S T R A C T
Serratia fonticola is an unusual human pathogen, previously described primarily as causing skin and soft
tissue infections following trauma. There is little information in the literature about its treatment or
susceptibilities. We describe the case of a 67-year-old male with paraplegia who developed urosepsis
due to S. fonticola. Blood and urine cultures obtained prior to the initiation of antimicrobials both grew
S. fonticola. The patient completed a 15-day course of antimicrobials and had an uneventful recovery.
We reviewed 17 other patients with clinical cultures positive for S. fonticola. Of these, 11 isolates were
from the genitourinary system, most often as part of a polymicrobial culture. The majority of the other
organisms recovered were recognized pathogens from the Enterobacteriaceae family. The cases suggest
that when recovered in conjunction with other organisms, S. fonticola does not lead to enhanced
virulence or worse clinical outcomes and may be a bystander. When detected alone, which is a rare
occurrence, S. fonticola may function as a human pathogen.
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vomiting. He told the staff that he felt like he had a urinary tract
infection and underwent a non-traumatic exchange of his
indwelling urethral catheter. A urinalysis obtained from the new
catheter showed clear yellow urine with 2+ bacteria, 3 red blood
cells per high-powered ﬁeld (hpf), 66 white blood cells (WBC) per
hpf, WBC clumps, mucus and sediment.
Within 6 h following the catheter change, he developed a fever
to 101.18F accompanied by hypotension (97/65 mmHg). The staff
observed he was exhibiting signs of mild delirium; his physical
examwas otherwise at baseline. Laboratory values included aWBC
count of 9.7 103 cells per mL with 75% neutrophils, <1%
granulocytes and a creatinine of 0.8 mg/dL. Blood and urine
cultures were obtained prior to the patient being empirically
started onpiperacillin/tazobactam. He also received supportive care
measures, including intravenous ﬂuids, antiemetics and antipyre-
tics. Within 24 h, he defervesced and resumed normal oral intake.
Blood cultures grew S. fonticola and urine cultures grew
>100,000 colony forming units per mL of S. fonticola and
Providencia stuartii. The S. fonticola isolates were susceptible to
ciproﬂoxacin, trimethoprim/sulfamethoxazole, cefepime, pipera-
cillin/tazobactam and carbapenems and were resistant to ampi-
cillin, cefazolin and ampicillin/sulbactam. Of note, the isolates
were resistant to gentamicin but susceptible to amikacin.
Following the availability of S. fonticola susceptibilities, he
completed a total of 2 weeks of antimicrobials with oral
ciproﬂoxacin and had an uneventful recovery.
Case series
Given the paucity of information about S. fonticola infections,
we sought to more completely describe the range of clinical
pathology associated with this organism. After obtaining approval
from the Institutional ReviewBoard at the authors’ Veterans Affairs
Medical Centers, we queried the microbiology database and
identiﬁed an additional 17 patients from 1999 to 2015 with
clinical cultures positive for S. fonticola. Table 1 summarizes these
cases as well as the 5 previous case reports [9].
Two of the patients had polymicrobial bacteremia related to
mucosal injury of the gut. Among 4 other patients, S. fonticola was
one of several organisms recovered from superﬁcial wound
cultures. One of these was an elderly male with end-stage renal
disease who developed a surgical site infection following
placement of a ﬁstula. Three others were diabetics with peripheral
vascular disease and foot infections severe enough to warrant
surgical debridement.
Notably, the remaining 11 cases were patients with urine
cultures that grew S. fonticola. Only 3 of the 11 cultures grew
S. fonticola alone, while the remaining 8 grew a variety of Gram-
positive and Gram-negative bacteria. Of these 11 cases, 5 patients
had clinical signs and symptoms consistent with urinary tract
infections (UTIs), while the remaining 6 had asymptomatic
bacteriuria. Among the 5 patients with UTIs, 2 had S. fonticola
alone, while the remaining 3 had polymicrobial urine cultures. In
this series of seventeen cases, the presence of S. fonticola did not
appear to confer any increased virulence or distinct features.
Table 2 details the antimicrobial susceptibilities of the S. fonticola
isolates described above.
Discussion
To the best of our knowledge this is the second report of
S. fonticola blood-stream infection in humans, and the third report
of such an infection in a vertebrate [10]. Our retrospective medical
record review identiﬁed an additional two patients who had
S. fonticola bacteremia, though in those cases it was not the sole
pathogen. Four previous case reports detail S. fonticola infections
secondary to trauma. Farmer et al. found 13 species from clinical
specimens (11 from wound cultures, 2 from the respiratory tract)
while Stock et al. assessed 6 clinical specimens, reporting only one
from urine and another one from a bloodstream infection (with no
description of clinical details) [3,11].
Given that the majority of S. fonticola isolates in our medical
system came from urine cultures, we postulate that this organism
may be part of the microbiota inhabiting the gastrointestinal tract.
This is supported by the 2 cases of polymicrobial bacteremia in
patients with injury of their intestinal mucosa. It is surprising that
no prior reports of S. fonticola in urinary specimens exist, which
raises the possibility that this organismmay only be an occasional
member of the gastrointestinal microbiota. Van Hoek et al.
Table 1
Summary of Serratia fonticola cases described in the literature and in this report.
Clinical syndromea Cases reported Cultures with S. fonticola only Cases with polymicrobial cultures References
Gram-positive cocci Gram-negative rodsb
Bacteremia 4 2 1 1 This report and [4]
Skin and soft tissue infection 7 1 6 6 This report and [5–7]
Urinary tract infectione,d 5 2 1 3 This report
Asymptomatic bacteriuriac,d 6 1 3 3 This report
Diarrhea 1 1e – – [8]
a Most severe clinical syndrome reported (i.e., a patient with bacteremia and urinary tract infection is reported only as bacteremia).
b Other than S. fonticola.
c Determination of whether the positive urine culture represented a urinary tract infection or asymptomatic bacteriuria was made using the criteria detailed by Hooten
et al. [14] and Loeb et al. [15] for patients with and without indwelling urinary catheters, respectively.
d Includes 1 patient with a nephrostomy tube(s).
e Sole organism isolated on selective media.
Table 2
Antimicrobial susceptibilities of S. fonticola isolates described in this report.
Antimicrobial Number of isolates tested Susceptiblea,b
Ampicillin 18 0 (0%)
Ampicillin–sulbactam 15 4 (27%)
Piperacillin–tazobactam 14 13 (93%)
Cefazolinc 19 2 (11%)
Cefepime 14 14 (100%)
Ceftriaxone 10 9 (90%)
Ertapenem 9 9 (100%)
Imipenem 11 10 (91%)
Ciproﬂoxacin 18 14 (78%)
Levoﬂoxacin 9 5 (78%)
Gentamicin 13 12 (93%)
Nitrofurantoin 11 1 (9%)
Trimethoprim–sulfamethoxazole 20 8 (40%)
a Number (percent).
b Unless otherwise noted, based on the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) Clinical breakpoints for bacteria v 6.0 [16].
c Based upon the 2014 Clinical and Laboratory Standards Institute breakpoints
for uncomplicated urinary tract infections or blood, depending on the sample [17].
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detected S. fonticola on a variety of retail vegetables, suggesting
ample opportunities for exposure, including through ingestion
[12]. Prior reports on wounds and respiratory tracts, nevertheless,
are rare enough to question how often humans are truly colonized
by this organism.
While human infections described so far have not presented a
therapeutic challenge in terms of resistance, S. fonticola has the
potential of harboring resistance elements, including a chromo-
somal inducible AmpC beta-lactamase. Van Hoek et al. found an
inducible FONA-type extended spectrum beta-lactamase (ESBL)
associated with resistance to third generation cephalosporins in
isolates from retail vegetables [12]. While a chromosomal enzyme
in S. fonticola, the same ESBL exists on a self-transferrable plasmid
in Enterobacter cloacae [13]. There is a theoretical risk that S.
fonticola could transmit these resistance elements to other
bacteria. The antimicrobial susceptibility data from our clinical
specimens, as well as previous reports, indicate that extended-
spectrum cephalosporins, carbapenems and ﬂuoroquinolones are
the best options for empiric treatment of true S. fonticola infections.
Based upon this case series of clinical cultures from ourmedical
system, S. fonticola appears to remain an unusual human pathogen
and is more commonly a bystander in polymicrobial infections
than previously appreciated.
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